Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen

Santos, Stephanie A.; Uriel, Alison; Park, James S.; Lucas, Jennifer L.; Carriero, Damaris; Jaffe, David L.; Dieterich, Douglas T.

doi:10.1097/01.meg.0000243877.17444.5e

Cited by 24 publications

(19 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(Continued) a single pill under the trade name Truvada; Gilead Sciences, Foster City, CA), may achieve greater viral suppression, as long as no adefovir mutations have developed [31,32]. In a recent abstract, Berg et al [33] showed that tenofovir and tenofovir/emtricitabine are equivalent in achieving viral suppression in patients with adefovir failure; the virus was undetectable in 81% after 1 year of therapy.…”

Section: Adefovir-experienced Patientsmentioning

confidence: 95%

Role of combination therapy in chronic hepatitis B

Scott

McMahon²

2009

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Combination therapy includes the use of two or more antivirals for the treatment of chronic hepatitis B. No study has shown that combination therapy is superior to monotherapy in naive patients for achieving treatment end points, but combination appears to result in a lower incidence of resistance. Moreover, the higher-potency compounds have not yet been studied. Consideration should be given to treating lamivudine-resistant patients with combination therapy, preferably with a nucleotide analogue in conjunction with a nucleoside analogue. Combination therapy should be considered in patients with decompensated cirrhosis who are unable to achieve an undetectable viral level on monotherapy and in naive patients who still have a detectable viral level 6 to 12 months after starting therapy.

show abstract

Section: Adefovir-experienced Patientsmentioning

confidence: 95%

Role of combination therapy in chronic hepatitis B

Scott

McMahon²

2009

Curr Gastroenterol Rep

View full text Add to dashboard Cite

show abstract

“…AZT/3TC has been associated with a higher rate of side effects than TDF/FTC, including gastrointestinal symptoms, anemia, and lipoatrophy [37]. However, AZT/3TC has the longest history of clinical experience in pregnant women as part of PMTCT and is still frequently used in this setting.…”

Section: Nrti Optionsmentioning

confidence: 98%

“…An open-label study, GS934, randomized treatment-naïve patients to either TDF/FTC or AZT/3TC, each with EFV. The TDF/FTC regimen demonstrated superior virologic and immunologic effects compared with AZT/3TC, owing in large part to a higher rate of discontinuation because of adverse events in the AZT/3TC arm [37]. When compared with stavudine or AZT, TDF-based treatment is associated with a significantly lower rate of lipoatrophy [38].…”

Section: Nrti Optionsmentioning

confidence: 99%

“…The most important adverse event associated with TDF treatment is nephrotoxicity. Multiple studies have shown that clinically signifi cant renal dysfunction with TDF is rare in treatment-naïve patients with normal baseline renal function [37]. Although renal complications are rare, patients on TDF should have periodic creatinine monitoring and alternative NRTIs should be considered for patients with baseline impaired renal function [40].…”

Section: Nrti Optionsmentioning

confidence: 99%

See 1 more Smart Citation

Antiretroviral therapy for treatment-naïve patients: A review of recent literature and the updated guidelines

Johnson¹,

Sax

2009

Curr Infect Dis Rep

View full text Add to dashboard Cite

The improved efficacy and safety of antiretroviral agents have fundamentally changed the face of HIV infection. Advances in antiretroviral therapy have dramatically improved the prognosis of HIV infection, which is now on a par with other chronic illnesses. This article addresses the optimal timing of antiretroviral therapy initiation and the optimal drug choices for initial regimens, with a focus on recent data and published guidelines issued by the US Department of Health and Human Services and the International AIDS Society-USA.

show abstract

“…The restriction fragment mass polymorphism revealed 11 amino acid substitutions in the rt domain of the HBV polymerase leading to rtA181V, rtN236T, and rtA181T mutations associated with HBV DNA rebound. Alternative therapeutic strategy includes switch from adefovir to tenofovir, or a combination of tenofovir and emtricitabine therapy, which achieve efficacy without any renal toxicity [82].…”

Section: Management Of Adefovir Resistancementioning

confidence: 99%

Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues

Leung

2008

Hepatol Int

View full text Add to dashboard Cite

Forty years ago in 1967, Professor Blumberg discovered the Australian Antigen, later known as the hepatitis B surface antigen, and was awarded the Nobel Prize. This discovery enables the diagnosis of hepatitis B virus (HBV) infection and defines its epidemiology. Viral hepatitis B infection affects global health situation, and chronic hepatitis B (CHB) is particularly serious in the Asia-Pacific region. HBV vaccines created the first breakthrough in HBV prevention. Through universal HBV vaccination program for the newborns, promoted since the mid-1980s, the main route that perpetuates chronic infection from mother to child is curbed. Most children and young adults now have immunity against HBV infection. The next breakthrough comes with therapy for CHB. This prevents progression to cirrhosis and hepatocellular carcinoma. Standard interferon therapy with modest efficacy has been largely replaced by therapy with nuclos(t)ide analogues or pegylated interferons alfa-2a and -2b. Lamivudine was approved by the FDA USA in 1998, followed by adefovir dipivoxil in 2002, entecavir in 2005, and telbivudine in 2006. Clevudine, tenofovir, and many promising candidates are in different stages of development and clinical trial. This paper critically reviews recent data published or presented since the APASL Consensus and Guideline Update of 2005. Clinical efficacy mostly in patients with raised serum alanine aminotransferase will be analyzed.

show abstract

Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen

Cited by 24 publications

References 33 publications

Role of combination therapy in chronic hepatitis B

Role of combination therapy in chronic hepatitis B

Antiretroviral therapy for treatment-naïve patients: A review of recent literature and the updated guidelines

Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues

Contact Info

Product

Resources

About